Observational analysis highlights the treatment-biomarker interaction affecting recurrence risk in patients, suggesting changes may improve outcomes.
Key Points
High cytotoxic T-cell density correlated with poorer 15-year invasive disease-free survival (iDFS) in high-risk patients.
A treatment-biomarker interaction implied chemotherapy is less effective with increased stromal CD8 density, indicating significant clinical implications.
Focus on macrophage and T-helper cells reveals their dual role in regulating cytotoxic T-cells in breast cancer.
The study identified a candidate biomarker that could offer potential treatment adjustments for around 50% of patients with Intermediate risk.